{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:59Z","timestamp":1792597619856,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ard.2025.06.2131","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T11:14:43Z","timestamp":1754565283000},"page":"1888-1899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1016","volume":"84","author":[{"given":"Peter A.","family":"Merkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran K.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Khalidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"B\u00f6rjesson Sj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin N.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Necander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rodr\u00edguez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2025.06.2131_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.06.2131_bib0002","article-title":"Eosinophilic granulomatosis with polyangiitis - advances in pathogenesis, diagnosis, and treatment","volume":"10","author":"Fijolek","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.ard.2025.06.2131_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.06.2131_bib0004","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.06.2131_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003956","article-title":"Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis","volume":"10","author":"Scherbacher","year":"2024","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.ard.2025.06.2131_bib0006","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/02770903.2017.1353612","article-title":"The impact of long-term systemic glucocorticoid use in severe asthma: a UK retrospective cohort analysis","volume":"55","author":"Daugherty","year":"2018","journal-title":"J Asthma"},{"key":"10.1016\/j.ard.2025.06.2131_bib0007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.ard.2025.06.2131_bib0008","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.06.2131_bib0009","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"20","key":"10.1016\/j.ard.2025.06.2131_bib0010","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ard.2025.06.2131_bib0011","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2025.06.2131_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14333","article-title":"Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: a meta-analysis of eight studies","volume":"55","author":"Spataro","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ard.2025.06.2131_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/Ralpha biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ard.2025.06.2131_bib0014","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2025.06.2131_bib0015","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1016\/S2665-9913(23)00243-6","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study","volume":"5","author":"Bettiol","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.06.2131_bib0016","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaip.2024.01.006","article-title":"Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Nanzer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.ard.2025.06.2131_bib0017","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ard.2025.06.2131_bib0018","unstructured":"European Medicines Agency. Nucala [Internet]; 2015 [cited 2024 Oct 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala"},{"key":"10.1016\/j.ard.2025.06.2131_bib0019","unstructured":"Food and Drug Administration. FDA approves first drug for eosinophilic granulomatosis with polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome [Internet]; 2017 [cited 2017 Dec 12]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-eosinophilic-granulomatosis-polyangiitis-rare-disease-formerly-known-churg"},{"issue":"1","key":"10.1016\/j.ard.2025.06.2131_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.06.2131_bib0021","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ard.2025.06.2131_bib0022","unstructured":"Food and Drug Administration. Fasenra prescribing information [Internet]; 2017 [cited 2024 Sept 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf"},{"key":"10.1016\/j.ard.2025.06.2131_bib0023","unstructured":"European Commission. Fasenra product information [Internet]; 2018 [cited 2024 Dec 24]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1252.htm"},{"key":"10.1016\/j.ard.2025.06.2131_bib0024","unstructured":"AstraZeneca. Fasenra 30mg subcutaneous injection syringe\/pen approved in Japan for eosinophilic granulomatosis with polyangiitis (EGPA) [Internet]; 2024 [cited 2025 Jan 10]. Available from: https:\/\/www.astrazeneca.co.jp\/media\/press-releases1\/2024\/2024122703.html"},{"issue":"5","key":"10.1016\/j.ard.2025.06.2131_bib0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.06.2131_bib0026","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.ard.2025.06.2131_bib0027","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","article-title":"Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.06.2131_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/art.43146","article-title":"Long-term safety and efficacy of mepolizumab in eosinophilic granulomatosis with polyangiitis","author":"Wechsler","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.06.2131_bib0029","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/rccm.202003-0729LE","article-title":"Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma","volume":"202","author":"Moran","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ard.2025.06.2131_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103398","article-title":"Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a European real-life retrospective comparative study","volume":"153","author":"Mattioli","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ard.2025.06.2131_bib0031","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.06.2131_bib0032","doi-asserted-by":"crossref","first-page":"AB430","DOI":"10.1016\/j.jaci.2024.12.981","article-title":"L07 Two-year efficacy and safety of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis","volume":"155","author":"Wechsler","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725041858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725041858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:14:32Z","timestamp":1779855272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725041858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0003496725041858"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.06.2131","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.06.2131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}